Biolidics Limited

Biolidics collaborates with Hangzhou Normal University to undertake clinical investigations for lung cancer biomarker

SINGAPORE (Sept 9): Biolidics, the medical technology company, is collaborating with Hangzhou Normal University to undertake clinical investigations to validate the clinical utility of CTCs as a biomarker in late stage lung cancer.

In addition, the group’s liquid biopsy solutions will be used as a companion diagnostics test to validate a combination treatment for lung cancer.

The liquid biopsy solutions separate cancer cells from a small amount of blood sample. The clinical studies serve to validate the clinical utility of CTCs as a biomarker in late stage lung cancer.

Biolidics partners Japan's Sysmex Corp for cancer-related R&D

SINGAPORE (Feb 20): Biolidics Limited has established a strategic partnership with Sysmex Corporation, a Tokyo Stock Exchange-listed supplier of hematology instruments, to collaborate on the development of laboratory assays in the field of circulating tumour cells.

See: Biolidics selling 27.5 mil new shares at 28 cents each in conjunction with Catalist listing

Be informed of the stories that matter

Subscribe

Be informed of the stories that matter